J&J's Caplyta clears phase 3 for bipolar mania, widening label path
A positive phase 3 result moves Caplyta closer to approval for bipolar manic episodes, building on its blockbuster sales and J&J's $14.6 billion acquisition.
Johnson & Johnson's antipsychotic Caplyta has notched its first phase 3 win in bipolar-associated manic episodes, according to a company announcement. The trial's success puts the drug on track for a broader psychiatric label, potentially covering acute mania in addition to its existing uses for schizophrenia and bipolar depression.
The positive readout comes as J&J's $14.6 billion bet on Intra-Cellular Therapies continues to pay off. Caplyta has already reached blockbuster sales status, and this new indication could further expand its market. The company said it plans to discuss the data with regulators, though no specific timeline for a submission was given in the source.
Because there is only one source, there are no conflicting accounts to reconcile. The source frames the result as a firm step forward, but notes that the trial is the first phase 3 win for this specific indication, leaving room for additional regulatory hurdles before approval.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.